Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban in NVAF with High Creatinine Clearance
NCT02964949Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 4, randomised, double-blind trial of edoxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Average Concentration of Edoxaban at Steady State, Minimum Concentration of Edoxaban in Plasma and 1 more. Started Jan 2017; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02964949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964949.